Amicus Therapeutics, Inc. (FOLD)
| Market Cap | 4.40B |
| Revenue (ttm) | 598.70M |
| Net Income (ttm) | -14.06M |
| Shares Out | 308.53M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | 59.72 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,125,132 |
| Open | 14.24 |
| Previous Close | 14.25 |
| Day's Range | 14.23 - 14.28 |
| 52-Week Range | 5.51 - 14.36 |
| Beta | 0.46 |
| Analysts | Buy |
| Price Target | 27.56 (+93.4%) |
| Earnings Date | Feb 18, 2026 |
About FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration an... [Read more]
Financial Performance
In 2024, Amicus Therapeutics's revenue was $528.30 million, an increase of 32.29% compared to the previous year's $399.36 million. Losses were -$56.11 million, -62.99% less than in 2023.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price target is $27.56, which is an increase of 93.40% from the latest price.
News
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicu...
BioMarin: Amicus Buyout Sparks My Enthusiasm
BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example,...
BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.
It's the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.
BioMarin to Buy Amicus Therapeutics for $4.8 Billion
BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.
BioMarin to acquire Amicus Therapeutics for $4.8 Billion
BioMarin Pharmaceutical said on Friday it will acquire Amicus Therapeutics in an all-cash deal worth about $4.8 billion.
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Milli...
Amicus Therapeutics: Moving Towards Consistent Profitability
Amicus Therapeutics (FOLD) is progressing toward profitability, driven by strong Q3 results and expanding global approvals for its rare disease therapies. FOLD's revenue grew 19.5% year-over-year, wit...
Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript
Amicus Therapeutics, Inc. ( FOLD) UBS Global Healthcare Conference 2025 November 10, 2025 2:45 PM EST Company Participants Jeffrey Castelli - Chief Development Officer Presentation Unknown Analyst Gr...
Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript
Amicus Therapeutics, Inc. ( FOLD) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - CEO, President & Di...
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N...
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, ...
Amicus Therapeutics: Turning The Corner To Profitability With 2 Developing Therapies
Amicus Therapeutics remains a Buy, supported by strong momentum in Galafold and Pombiliti/Opfolda, both with blockbuster potential. FOLD's Galafold leads in Fabry disease as the first oral precision m...
3 Of My Favorite Biotech Stocks Under $10
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited ...
Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 3:20 PM EDT Company Participants Sebastien Martel - Chief Business Officer Jeffrey Ca...
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Cl...
In NCLA Amicus Win, en Banc Federal Circuit Rules Trump's Emergency Tariffs Are Unlawful
V.O.S. Selections, Inc.; Plastic Services and Products, LCC, d/b/a Genova Pipe; MicroKits, LCC; FishUSA Inc.; Terry Precision Cycling LLC v. President Donald J. Trump, et al. V.O.S. Selections, Inc.; ...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...
Multiple Jewish Organizations File Second Circuit Amicus Brief in Support of Previously Detained Tufts Student
SEATTLE--(BUSINESS WIRE)--A coalition of American Jewish organizations have filed an amicus brief in the United States Court of Appeals for the Second Circuit in support of a Vermont federal court's c...
In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump
People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al. People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al.
The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination
Physicians file amicus brief opposing removal of religious exemptions to vaccines. Objections include components derived from pork or aborted fetal tissue.
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200
Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA, targeting $1 billion in revenue by 2028. The DMX-200 licensing deal opens a major market opportun...
Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley L. Campbell - CEO...
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold ® Q2 Revenue of $128.9M, up 12% at CER Pombiliti ® + Opfolda ® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance includin...
In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data
American Securities Association and Citadel Securities LLC v. U.S. Securities and Exchange Commission American Securities Association and Citadel Securities LLC v. U.S. Securities and Exchange Commiss...